| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | |
| Description | TNF receptor superfamily member 17 | ||||
| Gene symbol | GPRC5D | Synonyms | None | Type of gene | protein-coding |
| Chromosome | 12 | Map location | 12p13.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | G protein-coupled receptor class C group 5 member D | ||||
| GTO ID | GTC3683 |
| Trial ID | NCT06153251 |
| Disease | Multiple Myeloma |
| Altered gene | BCMA|GPRC5D |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | BMS-986453 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma |
| Year | 2024 |
| Country | France|Germany|Spain|United States |
| Company sponsor | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company |
| Other ID(s) | CA119-0002 |
| Cohort 1 | |||||||||
|
|||||||||